You are viewing: South Korea AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The South Korea AI in Life Science Market was valued at $456.6 Million in 2026 and projected to reach to $1466.5 Million by 2031, representing a compound annual growth rate of 26.3%. South Korea's AI in Life Science market is poised for exceptional growth through 2031, driven by increasing adoption of AI in drug discovery, clinical diagnostics, and personalized medicine.

South Korea AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea AI in Life Science Market Trends and Insights

  • South Korea's advanced healthcare infrastructure and strong investment in biotechnology position the country as a regional leader in AI-driven life science innovation.
  • The market growth in South Korea is driven by increasing adoption of AI in drug discovery, genomics, and personalized medicine, supported by government initiatives and private sector collaboration. South Korea's life science sector benefits from a highly educated workforce and robust R&D capabilities that accelerate AI implementation across pharmaceutical and diagnostic companies.
  • Between 2026 and 2031, South Korea is expected to see significant expansion in AI applications for clinical decision support, medical imaging analysis, and biomarker identification.
  • South Korea's competitive advantage in semiconductor and software development further strengthens its position in deploying cutting-edge AI solutions within the life science ecosystem..

Key Market Statistics

  • CAGR (2026-2031) 26.3% CAGR
  • Market Size, 2026 ~USD 456.6 Million
  • Forecast, 2031 ~USD 1466.5 Million
  • Country South Korea

South Korea AI in Life Science Market Overview

Rapid Market Expansion :

South Korea's AI in Life Science market is projected to grow from $456.6 million in 2026 to $1,466.5 million by 2031, representing a robust 26.3% CAGR and demonstrating exceptional market momentum in the region.

Advanced Healthcare Infrastructure :

South Korea's state-of-the-art healthcare system and digital-first approach provide an ideal foundation for AI integration, enabling faster adoption of AI-driven diagnostic and therapeutic solutions across hospitals and research institutions.

Biotechnology Investment Hub :

The country's strong government support and private sector investment in biotechnology create a favorable ecosystem for AI-powered drug discovery, genomics analysis, and personalized medicine development.

Regional Leadership Position :

South Korea is establishing itself as a regional leader in AI-driven life science innovation, attracting international partnerships and positioning local companies as key players in the Asia-Pacific market.

South Korea AI in Life Science Market Dynamics

  • The country's combination of advanced healthcare infrastructure, substantial biotechnology investments, and government initiatives supporting digital health transformation creates a compelling growth environment.
  • South Korea's tech-savvy population and strong pharmaceutical sector further accelerate AI implementation across life science applications.
  • Market expansion will be supported by rising healthcare costs driving efficiency demands, increased R&D spending by local biotech firms, and growing collaboration between technology companies and healthcare providers to develop innovative AI solutions..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • South Korea's AI in Life Science market will grow from $456.6M (2026) to $1,466.5M (2031), representing a 26.3% CAGR.
    • South Korea's advanced healthcare infrastructure and government support are key drivers of AI adoption in pharmaceutical and diagnostic sectors.
    • South Korea's semiconductor and software expertise provide competitive advantages in developing AI solutions for life science applications.
    • South Korea is positioned as a regional hub for AI-driven innovation in drug discovery, genomics, and personalized medicine by 2031.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    South Korea AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    Target Audience

    • Pharmaceutical & Biotech Companies : South Korean and international pharma firms need market intelligence to identify AI integration opportunities, assess competitive landscape, and plan R&D investments in drug discovery and development.
    • Healthcare Technology Providers : AI software and healthcare IT vendors require detailed market data to understand adoption rates, regulatory environment, and customer needs specific to South Korea's healthcare system.
    • Investment & Private Equity Firms : Investors evaluating South Korea's life science sector need comprehensive market sizing and growth projections to identify promising portfolio companies and assess regional expansion opportunities.
    • Government & Policy Makers : South Korean health ministry and innovation agencies require market data to inform policy decisions, funding allocations, and strategic initiatives supporting AI adoption in life sciences.
    • Healthcare Institutions & Hospitals : Major medical centers and research institutions need market insights to benchmark AI adoption, identify best practices, and plan digital transformation initiatives aligned with market trends.

    Key Companies in the South Korea AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for South Korea ($456.6M in 2026, $1,466.5M in 2031) to support investment decisions, business planning, and competitive positioning in this high-growth regional market.
    • Regional Opportunity Assessment : Understand South Korea's unique position as a regional AI life science leader, enabling identification of market entry strategies, partnership opportunities, and competitive advantages specific to the Korean market.
    • Sector-Specific Insights : Access detailed analysis of AI applications in South Korean drug discovery, diagnostics, and personalized medicine to identify the most promising segments for product development and commercialization.
    • Strategic Investment Planning : Leverage comprehensive market data to evaluate South Korea as an investment destination, assess growth potential, and benchmark performance against global and regional competitors.
    • Stakeholder Communication : Utilize credible market research to support board presentations, investor pitches, and strategic communications regarding South Korea's emerging opportunities in AI-driven life science innovation.

    Frequently asked questions

    What is the current size of South Korea's AI in Life Science market?

    South Korea's AI in Life Science market is valued at $456.6 million in 2026 and is expected to grow to $1,466.5 million by 2031.

    What is the projected growth rate for South Korea's AI in Life Science market?

    South Korea's AI in Life Science market is projected to grow at a compound annual growth rate (CAGR) of 26.3% from 2026 to 2031.

    What are the main drivers of AI adoption in South Korea's life science sector?

    South Korea's AI adoption is driven by advanced healthcare infrastructure, government initiatives, strong R&D capabilities, and applications in drug discovery, genomics, and personalized medicine.

    How does South Korea's technology sector support AI in life science?

    South Korea's competitive advantages in semiconductors and software development enable the creation and deployment of cutting-edge AI solutions tailored for life science applications.

    What AI applications are most prevalent in South Korea's life science market?

    South Korea's life science sector is increasingly adopting AI for clinical decision support, medical imaging analysis, drug discovery, biomarker identification, and personalized medicine.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status